Cite
HARVARD Citation
Al-Riyami, A. et al. (n.d.). Sorafenib is effective for imatinib-resistant FIP1L1/PDGFRA T674I mutation-positive acute myeloid leukemia with eosinophilia. Leukemia & lymphoma. 54 (8), pp. 1788-1790. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Al-Riyami, A. et al. (n.d.). Sorafenib is effective for imatinib-resistant FIP1L1/PDGFRA T674I mutation-positive acute myeloid leukemia with eosinophilia. Leukemia & lymphoma. 54 (8), pp. 1788-1790. [Online].